Back

News

Category

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

Read More

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

August 24. Treatment with its antibody directed against tumor lymphocytes offers new hope for patients with PTCL

Read More

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

Read More

Reflections on #AACR2024: our key insights and contributions

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

Read More

XENOTHERA announces the start of the second dose cohort in the FIPO trial

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Read More

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

February, 2024. For almost ten years, XENOTHERA has been committed to tackling...

Read More

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

November 27, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

October 25, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XENOTHERA strengthens its management team and governance.

June 8, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

May 30, 2023. # Download our press release (english version) # Télécharger...

Read More

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

April 5,2023. # Télécharger notre communiqué de presse (version française)  

Read More

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

April 3, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

January 05,2023. # Download our press release (english version)  

Read More

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

Read More

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

December 19, 2022. # Download our press alert (english version) # Télécharger...

Read More

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

December 16,2022. # Download our press release (english version) # Télécharger notre...

Read More

[Newsletter] XENONEWS

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

Read More

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

Read More

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

Read More

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

Read More

[ Press Information ] APPOINTMENTS

April 2022. # Download our press information (english version) # Télécharger notre...

Read More

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

January 2022. # Download our press information (english version) # Télécharger notre...

Read More

[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.

# Download our press information (english version) # Télécharger notre information presse...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in